[
  {
    "page": 1,
    "text": "Pain Management: Competitor Analysis & Matrix. Strategy Document. 1. Competitive Landscape. Competing with NSAIDs and specialized muscle relaxants. 2. Head-to-Head Comparison. Advantage in speed and GI safety. Table 4: Competitor Matrix.",
    "sections": [
      {
        "id": "sec_1_1",
        "heading": "1. Competitive Landscape",
        "content": "Focuses on physical manifestations of pain vs traditional anti-inflammatories."
      }
    ],
    "tables": [
      {
        "id": "tab_1_1",
        "title": "Table 4: Competitor Matrix",
        "headers": ["Metric", "Veldra Zaloric", "Generic Ibuprofen", "Brand Naproxen", "Aetheris Nuvia"],
        "rows": [
          ["Category", "Muscle Relaxant", "NSAID", "NSAID", "Calming Agent"],
          ["Speed", "30-45 Min", "60+ Min", "90+ Min", "20-30 Min"],
          ["GI Stress", "Low", "High", "Medium-High", "Very Low"]
        ],
        "metadata": { "market_intelligence": true }
      }
    ]
  },
  {
    "page": 2,
    "text": "Sedation: Moderate vs None. Best For: Spasms vs Fever vs Anxiety. 3. Strategic Positioning: Body vs. Mind. Focus on physicality for Veldra. 4. Market Share Projection. Targeting 22% of back pain market.",
    "sections": [
      {
        "id": "sec_2_1",
        "heading": "3. Strategic Positioning: Body vs. Mind",
        "content": "Clarifies the sales angle: Veldra is for sharp, physical limits; Aetheris is for mental weight."
      },
      {
        "id": "sec_2_2",
        "heading": "4. Market Share Projection",
        "content": "Aims for 22% capture of generic NSAID market share."
      }
    ],
    "tables": []
  }
]